Hope for to-marrow: the status of paid peripheral blood stem cell donation under the National Organ Transplant Act

Todd, Kelly

doi:10.1093/jlb/lsx027

Cited by 2 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2011, the decision made by the US Court of Appeals for the 9 th Circuit made donor remuneration for peripheral blood stem cell collection (PBSC) legal in states within the Ninth Circuit [ 19 ]. This decision was followed by a heated debate in the medical and legal communities, with advocates arguing for payment as a necessary step to increase donations, while opponents believed the decision to be unethical, leading to exploitation of vulnerable populations [ 20 ]. The Department of Health and Human Services (HHS) initially filed an appeal against the decision.…”

Section: Overview Of the Global Regulatory Environment In Cell And Ge...mentioning

confidence: 99%

“…The Department of Health and Human Services (HHS) initially filed an appeal against the decision. Months later, however, the HHS appeal was withdrawn, bringing the 9th Circuit Court’s decision back into effect [ 20 ].…”

Section: Overview Of the Global Regulatory Environment In Cell And Ge...mentioning

confidence: 99%

“…Remuneration may also be morally problematic given its potential to attract financially disadvantaged persons. This argument was previously challenged by PBSC remuneration advocates, arguing that the low human leukocyte antigen (HLA) matching odds associated with the HCT donation system blunt the coercive nature of a paid market on financially disadvantaged individuals [ 20 ]. HLA matching in allogeneic cell therapies remains crucial to ensure the best possible outcome for patients, yet the specific uses of donor stem cells in CGT development make repeated donations from a single donor a possibility.…”

Section: Potential Threat To the Common Goodmentioning

confidence: 99%

See 2 more Smart Citations

Remuneration of donors for cell and gene therapies: an update on the principles and perspective of the World Marrow Donor Association

Hamad,

Ahmed,

van Eerden

et al. 2024

Bone Marrow Transplant

View full text Add to dashboard Cite

The cell and gene therapy (CGT) sector has witnessed significant advancement over the past decade, the inception of advanced therapy medicinal products (ATMPs) being one of the most transformational. ATMPs treat serious medical conditions, in some cases providing curative therapy for seriously ill patients. There is interest in pivoting the ATMP development from autologous based treatments to allogenic, to offer faster and greater patient access that should ultimately reduce treatment costs. Consequently, starting material from allogenic donors is required, igniting ethical issues associated with financial gains and donor remuneration within CGT. The World Marrow Donor Association (WMDA) established the Cellular Therapy Committee to identify the role WMDA can play in safeguarding donors and patients in the CGT field. Here we review key ethical principles in relation to donating cellular material for the CGT field. We present the updated statement from WMDA on donor remuneration, which supports non-remuneration as the best way to ensure the safety and well-being of donors and patients alike. This is in line with the fundamental objective of the WMDA to maintain the health and safety of volunteer donors while ensuring high-quality stem cell products are available for all patients. We acknowledge that the CGT field is evolving at a rapid pace and there will be a need to review this position as new practices and applications come to pass.

show abstract

Section: Overview Of the Global Regulatory Environment In Cell And Ge...mentioning

confidence: 99%

Section: Overview Of the Global Regulatory Environment In Cell And Ge...mentioning

confidence: 99%

Section: Potential Threat To the Common Goodmentioning

confidence: 99%

See 1 more Smart Citation

Remuneration of donors for cell and gene therapies: an update on the principles and perspective of the World Marrow Donor Association

Hamad,

Ahmed,

van Eerden

et al. 2024

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

Experiences of Unrelated Hematopoietic Stem-cell Donors and Experts of Relevant Institutions

Kim

et al. 2019

Korean J Adult Nurs

View full text Add to dashboard Cite

This study attempts to explore the experiences of Hematopoietic Stem Cell Donation (HSCD) among donors and experts of HSCD-related institutions in South Korea. Methods: In July 2017, 7 donors and 8 experts with experience of HSCD-related work were interviewed. The transcribed data were qualitatively analyzed to identify major themes and sub-themes representing the experiences of the donors and experts. Results: The analysis indicated that donors' HSCD-related experiences were structured into 5 themes ("Lack of understanding of HSCD", "Difficulty in decision-making regarding HSCD", "Major hassles involving HSCD", "Meaningful experiences and hopefulness" and "More effort by government and institutions for future donors"). The experts' experiences were structured into 4 themes ("Improving the donation procedure through government support", "Improving the donation procedure through campaign reinforcement", "Donors' characteristics", and "Meaning of my job"). Conclusion: HSCD-related institutions must manage donors more carefully. This would involve keeping them aware of what they are likely to experience throughout the donation procedure, follow-up monitoring, and continuous support. Efforts should be taken to inform nurses involved in HSCD of research on donors' experiences, and they must be systematically trained to ease donors' difficulties.

show abstract

Hope for to-marrow: the status of paid peripheral blood stem cell donation under the National Organ Transplant Act

Cited by 2 publications

References 5 publications

Remuneration of donors for cell and gene therapies: an update on the principles and perspective of the World Marrow Donor Association

Remuneration of donors for cell and gene therapies: an update on the principles and perspective of the World Marrow Donor Association

Experiences of Unrelated Hematopoietic Stem-cell Donors and Experts of Relevant Institutions

Contact Info

Product

Resources

About